Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection.

Abstract

Intrauterine infection with Ureaplasma spp. is strongly associated with preterm birth and adverse neonatal outcomes. We assessed whether combined intraamniotic (IA) and maternal intravenous (IV) treatment with one of two candidate antibiotics, azithromycin (AZ) or solithromycin (SOLI), would eradicate intrauterine Ureaplasma parvum infection in a sheep model of pregnancy. Sheep with singleton pregnancies received an IA injection of U. parvum serovar 3 at 85 days of gestational age (GA). At 120 days of GA, animals (n=5 to 8/group) received one of the following treatments: (i) maternal IV SOLI with a single IA injection of vehicle (IV SOLI only); (ii) maternal IV SOLI with a single IA injection of SOLI (IV+IA SOLI); (iii) maternal IV AZ and a single IA injection of vehicle (IV AZ only); (iv) maternal IV AZ and a single IA injection of AZ (IV+IA AZ); or (v) maternal IV and single IA injection of vehicle (control). Lambs were surgically delivered at 125 days of GA. Treatment efficacies were assessed by U. parvum culture, quantitative PCR, enzyme-linked immunosorbent assay, and histopathology. Amniotic fluid (AF) from all control animals contained culturable U. parvum. AF, lung, and chorioamnion from all AZ- or SOLI-treated animals (IV only or IV plus IA) were negative for culturable U. parvum. Relative to the results for the control, the levels of expression of interleukin 1β (IL-1β), IL-6, IL-8, and monocyte chemoattractant protein 2 (MCP-2) in fetal skin were significantly decreased in the IV SOLI-only group, the MCP-1 protein concentration in the amniotic fluid was significantly increased in the IV+IA SOLI group, and there was no significant difference in the histological inflammation scoring of lung or chorioamnion among the five groups. In the present study, treatment with either AZ or SOLI (IV only or IV+IA) effectively eradicated macrolide-sensitive U. parvum from the AF. There was no discernible difference in antibiotic therapy efficacy between IV-only and IV+IA treatment regimens relative to the results for the control.

• Authors: Yuichiro Miura, Matthew S Payne, Jeffrey A Keelan, Andres Noe, Sean Carter, Rory Watts, Owen B Spiller, Alan H Jobe, Suhas G Kallapur, Masatoshi Saito, Sarah J Stock, John P Newnham, Matthew W Kemp
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 58 Issue 9 Pg. 5413-20 (Sep 2014) ISSN: 1098-6596 [Electronic] United States
• PMID: 24982089 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Chemical References

• Anti-Bacterial Agents
• Chemokine CCL2
• Chemokine CCL8
• Interleukins
• Macrolides
• Triazoles
• Azithromycin
• solithromycin

Topics

• Administration, Intravenous (methods)
• Amniotic Fluid (drug effects, microbiology)
• Animals
• Anti-Bacterial Agents (pharmacology)
• Azithromycin (pharmacology)
• Chemokine CCL2 (metabolism)
• Chemokine CCL8 (metabolism)
• Female
• Fetus (drug effects)
• Interleukins (metabolism)
• Lung (drug effects, metabolism)
• Macrolides (pharmacology)
• Pneumonia (metabolism)
• Pregnancy
• Pregnancy Complications, Infectious (drug therapy, metabolism, microbiology)
• Sheep
• Triazoles (pharmacology)
• Ureaplasma (drug effects)
• Ureaplasma Infections (drug therapy, metabolism)